Vir Biotechnology Inc
VIR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.71B
Close$
$12.26
23.1% upside
Current Fair Value
23.1% upsideUndervalued by 23.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.71 Billion |
|---|---|
| Enterprise Value | $1.58 Billion |
| Earnings per Share | $-3.16 |
| Beta | 1.7 |
| Outstanding Shares | 169,275,049 |
Return
| Return on Equity | -20.62% |
|---|---|
| Return on Assets | -16.62% |
| Return on Invested Capital | -19.02% |
Valuation & Multiples
| P/E Ratio | -7.97 |
|---|---|
| PEG | 19.43 |
| Price to Sales | 9.96 |
| Price to Book Ratio | 1.99 |
| Enterprise Value to Revenue | 5.21 |
| Enterprise Value to EBIT | -8.05 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS
-$0.57
Est. -$0.77Revenue
-$188,000
Est. $1.14 MNext Earnings Call
Expected Date
February 22, 2027
EPS Estimate
-$0.12
Consensus analyst estimateRevenue Estimate
$87.44 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 1.00, calls and puts are about even.
| Put/Call Ratio | 1.0000▲ 45.87% |
|---|---|
| Total Calls | 50,000▼ 85.20% |
| Total Puts | 50,000▼ 72.66% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.35%▼ 74.85% |
|---|---|
| Total Invested | $250.31M▼ 83.40% |
| Investors Holding | 105▼ 141.00% |
About Vir Biotechnology Inc
327 employees
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are desi...